Sakara Digital https://validator.w3.org/feed/docs/rss2.html Selecting a LIMS in 2026: What to Look For Beyond Features AI-Powered Literature Surveillance in Pharmacovigilance Patient Data Privacy in Clinical Research: Navigating GDPR and FDA Expectations Green Chemistry and Sustainable Manufacturing: Digital Tools for Pharma’s Environmental Transformation ATMP Manufacturing Automation: Scaling Cell and Gene Therapy Production Through Digital Innovation EU Gene Therapy Standards: Navigating EMA’s Evolving Manufacturing and Quality Requirements The Purolea Letter: What Pharma’s First AI Warning Means for GxP Compliance mRNA Manufacturing Technology: Digital Infrastructure for Next-Generation Vaccine and Therapeutic Production FDA Digital Health Precertification: Lessons Learned and the Path Forward for Software Developers SAP S/4HANA Migration for Pharma: Planning the Transition Before 2027 End of Support Real-World Evidence Strategy: Building RWE Capabilities for Regulatory and Commercial Decision-Making Bioprocessing Digital Twins: Modeling Upstream and Downstream Operations for Process Optimization The Rise of the Electronic Trial Master File: From Digital Filing Cabinet to Compliance Intelligence Right-First-Time Manufacturing KPIs for Cell Therapy Sites AI Maturity Self-Assessment: A 30-Minute Diagnostic for Pharma IT Leaders Building a Digital-First Pharma Company: Lessons from Organizations Getting It Right Building a Right-First-Time Manufacturing Culture in Biopharma Supplier Quality Management for Pharma: What Good Looks Like in 2026 The DCT Hybrid Model That Actually Reduces Site Burden Adaptive Clinical Trial Designs in Rare Disease: When the Math Works How a Top-10 Pharma Validated Its First Production LLM in a GxP Environment (Public Case Pattern) Patient-Centric Drug Development: How to Make It Operational, Not Just Aspirational AI in Biomarker Discovery: Where the Field Stands in 2026 The Pharma M&A Digital Due Diligence Checklist Building a Cross-Functional AI Steering Committee That Doesn’t Stall AI Reference Architecture for a 500-Person Biotech (Not a Top 20 Pharma) Federated Learning in Pharma: Privacy-Preserving AI Across Organizations Vendor Qualification in a Cloud-First World: Adapting Your Process Annex 22 Mock Inspection: What a Pharma Quality Team Should Practice Now The Data Quality Debt Audit Pattern We Run With Clients EMA’s Annex 22 Implementation Timeline: Where Pharma Sponsors Stand in May 2026 Building a Data-Driven Culture in Life Sciences eTMF Best Practices for Digital-First Clinical Programs Periodic Review for AI Systems: What GxP Requires Reskilling Your Quality Team for AI Oversight: A 6-Month Curriculum The First Right-Sided Investigation Workshop We Run With Clients CAPA Effectiveness Reviews: The 90-Day Look-Back I Recommend The Quality Metrics Dashboard That Actually Drives Investigations to Closure What the McKinsey AI Playbook Misses for Pre-Revenue Biotech Talent Retention in Biopharma 2026: What the Data Says Continuous Improvement in GxP Environments: A Practical Framework SOP Authoring Pattern for AI-Augmented Manufacturing Operations What’s Changed in CSA Implementation Since 2024: A Practical 2026 Update The Data Lineage Tools Comparison for Pharma R&D in 2026 The Latest FDA Guidance on AI in Drug Manufacturing: April-May 2026 Update Biosimilar Commercialization Strategy: Navigating a Crowded Market Predictive Maintenance in Pharma Manufacturing: The ROI Case Deviation Management in the Age of Digital QMS Federated Learning Across Pharma Consortia: Lessons From Recent Deals The Pharma CIO’s Quarterly Board Update Template